Nehal N. Mehta, MD, MSCE
Year elected: 2018
Current membership category: Active
National Heart, Lung, and Blood Institute
Building 10-CRC Room 5-5140
Bethesda, MD 20814
United States of America
Phone: (301) 827-0483
Dr. Nehal Mehta is the head of the Laboratory of Inflammation and Cardiometabolic Diseases at the NHLBI Intramural Program at the NIH in Bethesda Maryland. Dr. Mehta’s research program focuses on the role of innate immunity and inflammation in the development of cardiovascular and metabolic diseases. He has utilized the chronic inflammation state observed in psoriasis, an inflammatory disease that visibly manifests as skin rashes to study the development of cardiometabolic diseases. Through a combination of laboratory, imaging, and clinical studies, Dr. Mehta helped shift the prevailing model of psoriasis, from thinking of it as just a skin disease to a disease of the whole body. His work has shown that people with psoriasis without CVD risk factors are at increased risk of CVD and future vascular events. Research from his lab has demonstrated that people with psoriasis have abnormal lipoprotein particle composition and impairment in high-density lipoprotein (HDL) efflux capacity. Dr. Mehta’s group was the first to utilize inflammatory imaging using positron emission tomography (PET) to demonstrate that patients with psoriasis have early onset of vascular disease and systemic inflammation. This imaging program has become a central outcome in several ongoing interventional studies in psoriasis to understand whether treatment of skin disease improves vascular disease.
He attended an accelerated 7-year biomedical program at George Washington University, where he received his bachelor’s degree with honors and medical degree with distinction. He also earned a master’s degree in clinical epidemiology from the University of Pennsylvania. Dr Mehta completed his internship, residency, and chief medical residency in internal medicine at the Hospital of the University of Pennsylvania, followed by a fellowship in cardiovascular diseases, nuclear cardiology, and preventive cardiology. The long term goals of Dr. Mehta’s lab are to improve both risk stratification and risk prediction for CVD in people with inflammatory conditions.